Roivant Sciences Stock Performance
| ROIV Stock | USD 10.90 0.04 0.37% |
Roivant Sciences has a performance score of 3 on a scale of 0 to 100. The company holds a Beta of 1.39, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Roivant Sciences will likely underperform. Roivant Sciences right now holds a risk of 2.3%. Please check Roivant Sciences maximum drawdown, as well as the relationship between the skewness and price action indicator , to decide if Roivant Sciences will be following its historical price patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Roivant Sciences are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak forward indicators, Roivant Sciences may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
Actual Historical Performance (%)
One Day Return (0.37) | Five Day Return 5.83 | Year To Date Return (3.96) | Ten Year Return 4.81 | All Time Return 4.81 |
1 | Roivant Sciences Ltd. Q3 2023 Earnings Call Transcript | 02/14/2024 |
2 | Payment of 16002 shares by Venker Eric of Roivant Sciences subject to Rule 16b-3 | 02/22/2024 |
3 | Disposition of 1630 shares by Richard Pulik of Roivant Sciences at 11.71 subject to Rule 16b-3 | 02/28/2024 |
4 | Sectoral Asset Management Inc. Boosts Stock Position in Roivant Sciences Ltd. | 03/06/2024 |
5 | Disposition of 45361 shares by Qvt Financial Lp of Roivant Sciences subject to Rule 16b-3 | 03/07/2024 |
6 | Roivant Sciences stock target raised to 16 by Goldman Sachs - Investing.com Australia | 03/13/2024 |
7 | Disposition of 10945 shares by Matthew Gline of Roivant Sciences at 10.01 subject to Rule 16b-3 | 03/20/2024 |
8 | Where Roivant Sciences Stands With Analysts - Roivant Sciences - Benzinga | 03/25/2024 |
9 | Disposition of 2341 shares by Richard Pulik of Roivant Sciences at 10.54 subject to Rule 16b-3 | 03/28/2024 |
10 | Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to 1.5 Billion Share Repurchase Program, Includi... | 04/02/2024 |
11 | Stocks Showing Improved Relative Strength Roivant Sciences - Investors Business Daily | 04/04/2024 |
12 | Disposition of 1856163 shares by Sukhatme Mayukh of Roivant Sciences subject to Rule 16b-3 | 04/05/2024 |
13 | Disposition of 3000000 shares by Vivek Ramaswamy of Roivant Sciences at 11.05 subject to Rule 16b-3 | 04/08/2024 |
14 | Arizona State Retirement System Buys 12057 Shares of Roivant Sciences Ltd. - Defense World | 04/17/2024 |
| Begin Period Cash Flow | 2.1 B | |
| Total Cashflows From Investing Activities | -44.3 M |
Roivant |
Roivant Sciences Relative Risk vs. Return Landscape
If you would invest 1,037 in Roivant Sciences on January 26, 2024 and sell it today you would earn a total of 53.00 from holding Roivant Sciences or generate 5.11% return on investment over 90 days. Roivant Sciences is currently generating 0.1061% in daily expected returns and assumes 2.298% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Roivant, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Roivant Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Roivant Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Roivant Sciences, and traders can use it to determine the average amount a Roivant Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0462
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ROIV | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.3 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Roivant Sciences is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Roivant Sciences by adding it to a well-diversified portfolio.
Roivant Sciences Fundamentals Growth
Roivant Stock prices reflect investors' perceptions of the future prospects and financial health of Roivant Sciences, and Roivant Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Roivant Stock performance.
| Return On Equity | 1.06 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | 36.24 % | ||||
| Operating Margin | (7.74) % | ||||
| Current Valuation | 2.87 B | ||||
| Shares Outstanding | 805.85 M | ||||
| Price To Book | 1.45 X | ||||
| Price To Sales | 71.53 X | ||||
| Revenue | 61.28 M | ||||
| Gross Profit | (477.06 M) | ||||
| EBITDA | (1.11 B) | ||||
| Net Income | (1.12 B) | ||||
| Cash And Equivalents | 1.94 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 481.4 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 6.20 X | ||||
| Book Value Per Share | 7.57 X | ||||
| Cash Flow From Operations | (843.39 M) | ||||
| Earnings Per Share | 5.27 X | ||||
| Market Capitalization | 8.82 B | ||||
| Total Asset | 2.39 B | ||||
| Retained Earnings | (3.77 B) | ||||
| Working Capital | 1.53 B | ||||
About Roivant Sciences Performance
To evaluate Roivant Sciences Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Roivant Sciences generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Roivant Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Roivant Sciences market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Roivant's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 88.28 | 83.87 | |
| Return On Tangible Assets | (0.63) | (0.66) | |
| Return On Capital Employed | (0.59) | (0.61) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (0.69) | (0.72) |
Things to note about Roivant Sciences performance evaluation
Checking the ongoing alerts about Roivant Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Roivant Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 61.28 M. Net Loss for the year was (1.12 B) with loss before overhead, payroll, taxes, and interest of (477.06 M). | |
| Roivant Sciences currently holds about 1.94 B in cash with (843.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Arizona State Retirement System Buys 12057 Shares of Roivant Sciences Ltd. - Defense World |
- Analyzing Roivant Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Roivant Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Roivant Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Roivant Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Roivant Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Roivant Sciences' stock. These opinions can provide insight into Roivant Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roivant Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Roivant Stock please use our How to Invest in Roivant Sciences guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Roivant Stock analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Roivant Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Roivant Sciences. If investors know Roivant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Roivant Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 5.27 | Revenue Per Share 0.16 | Quarterly Revenue Growth 1.178 | Return On Assets (0.14) | Return On Equity 1.058 |
The market value of Roivant Sciences is measured differently than its book value, which is the value of Roivant that is recorded on the company's balance sheet. Investors also form their own opinion of Roivant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Roivant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Roivant Sciences' market value can be influenced by many factors that don't directly affect Roivant Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Roivant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Roivant Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Roivant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.